Drug Trial Radar · NCT00696475
Diazoxide Choline in Hypertriglyceridemia
Last checked: Nov 19, 2026Latest source record: Nov 8, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Planned (sponsor's estimate)
Start
Jun 2008
Primary completion
Jan 2009
Study completion Mar 2009
Sponsor
- Lead sponsor
- Essentialis, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Jun 12, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hypertriglyceridemia affects 30% of the population in the US. Very high level of triglycerides is a known risk factor for pancreatitis. In addition, studies have shown that hypertriglyceridemia is an independent risk factor for cardiovascular disease. Diazoxide is a KATP channel opener. It has been approved by the FDA as an oral suspension for the treatment of hyperinsulinemic hypoglycemic conditions and as an IV solution for malignant hypertension. Preclinical and clinical studies suggest that diazoxide can be a potential therapeutic agent for hypertriglyceridemia. Diazoxide choline is a novel, highly crystalline proprietary salt of diazoxide, which has been formulated as a controlled-release tablet suitable for once per day dosing. This current study is designed to assess the effect of diazoxide choline on triglycerides in subjects with baseline hypertriglyceridemia. In addition, the effects on other lipid parameters, glucose and insulin, body weight as well as the safety and tolerability of diazoxide choline will be assessed.
Conditions
- Hypertriglyceridemia
Interventions
Diazoxide cholineDrug
Diazoxide cholineDrug
Diazoxide cholineDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the effect on triglycerides of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjectsTime frame: 8 weeks
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
National Research Institute
Los Angeles, California
Jacksonville Center for Clinical Research
Jacksonville, Florida
Allied Research International/Cetero Research
Miami Gardens, Florida
Meridien Research
Tampa, Florida
Midwest Institute for Clinical Research
Indianapolis, Indiana
L-MARC Research Center
Louisville, Kentucky
St. Luke's Lipid and Diabetes Research Center
Kansas City, Missouri
Piedmont Medical Research Associates
Winston-Salem, North Carolina
Metabolic and Atherosclerosis Research Center (MARC)
Cincinnati, Ohio
Sterling Research Group, Ltd
Cincinnati, Ohio
Frederick C. Smith Clinic
Marion, Ohio
TriCities Medical Research
Bristol, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.